GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Foundation Medicine Inc (NAS:FMI) » Definitions » Financial Strength

Foundation Medicine (Foundation Medicine) Financial Strength : 0 (As of Jun. 2018)


View and export this data going back to 2013. Start your Free Trial

What is Foundation Medicine Financial Strength?

Foundation Medicine has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Foundation Medicine did not have earnings to cover the interest expense. Foundation Medicine's debt to revenue ratio for the quarter that ended in Jun. 2018 was 0.48. As of today, Foundation Medicine's Altman Z-Score is 0.00.


Competitive Comparison of Foundation Medicine's Financial Strength

For the Diagnostics & Research subindustry, Foundation Medicine's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Foundation Medicine's Financial Strength Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Foundation Medicine's Financial Strength distribution charts can be found below:

* The bar in red indicates where Foundation Medicine's Financial Strength falls into.



Foundation Medicine Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Foundation Medicine's Interest Expense for the months ended in Jun. 2018 was $-1.5 Mil. Its Operating Income for the months ended in Jun. 2018 was $-32.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was $110.0 Mil.

Foundation Medicine's Interest Coverage for the quarter that ended in Jun. 2018 is

Foundation Medicine did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Foundation Medicine's Debt to Revenue Ratio for the quarter that ended in Jun. 2018 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2018 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 110) / 228.024
=0.48

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Foundation Medicine has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Foundation Medicine  (NAS:FMI) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Foundation Medicine has the Financial Strength Rank of 0.


Foundation Medicine Financial Strength Related Terms

Thank you for viewing the detailed overview of Foundation Medicine's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Foundation Medicine (Foundation Medicine) Business Description

Traded in Other Exchanges
N/A
Address
Foundation Medicine Inc is a molecular diagnostics company that specializes in the evaluation and treatment of cancer. Its products provide genetic information about a patient's cancer that is used by physicians to inform clinical decisions and by biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine's core molecular information products include FoundationOne, for solid tumors, and FoundationOne Heme, for blood-based cancers and hematologic malignancies. The vast majority of the firm's revenue is generated within the United States.
Executives
Alexis Borisy director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Vincent A. Miller officer: Chief Medical Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Jason Ryan officer: Chief Financial Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Troy Cox director, officer: President and CEO C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Robert W. Hesslein officer: SVP and General Counsel C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas Civik officer: Chief Commercial Officer C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Roche Finance Ltd director, 10 percent owner, other: See footnote (1) C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8
Roche Holding Ltd director, 10 percent owner, other: See footnote (1) ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Robert I Tepper 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Mark J Levin 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Third Rock Ventures Gp, L.p. 10 percent owner C/O THIRD ROCK VENTURES, 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116